Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 5/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.31 |
| ▸ | GLRA3 | O75311 | 3/20 | 0.31 |
| ▸ | GLRB | P48167 | 3/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4629092 | 0.89 | HSD11B1 (0.35) | — | |
| SCHEMBL4563791 | 0.89 | HSD11B1 (0.35) | — | |
| SCHEMBL4855306 | 0.88 | NR3C1 (0.35) | HTR2CHTR2BNR3C1PGR | |
| SCHEMBL4555633 | 0.86 | PGR (0.38) | HTR2CNR3C1PGR | |
| SCHEMBL4818005 | 0.83 | FFAR1 (0.39) | ALDH1A1MEN1KMT2APOLBTSHR | |
| SCHEMBL4848567 | 0.83 | PTGS2 (0.37) | — | |
| SCHEMBL4564249 | 0.81 | NR3C1 (0.31) | NR3C1PGR | |
| SCHEMBL4866562 | 0.81 | HSP90AA1 (0.34) | NR3C1PGRMEN1KMT2APOLB | |
| SCHEMBL4566271 | 0.81 | NR3C1 (0.40) | NR3C1PGRNR3C2 | |
| SCHEMBL4566100 | 0.81 | KMT2A (0.36) | PGRALDH1A1MEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423045-B2 | ABCA1 elevating compounds | CV THERAPEUTICS, INC. (US) | 2008-09-09 | — | — | US | claimed |
| US-20070010544-A1 | ABCA1 elevating compounds | CV THERAPEUTICS, INC. | 2007-01-11 | — | — | US | claimed |
| US-20080293757-A1 | ABCA1 ELEVATING COMPOUNDS | ABELMAN MATTHEW | 2008-11-27 | — | — | US | disclosed |
| US-7432276-B2 | ABCA1 elevating compounds | CV THERAPEUTICS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7423045-B2 | ABCA1 elevating compounds | CV THERAPEUTICS, INC. (US) | 2008-09-09 | — | — | US | disclosed |
| US-20070191379-A1 | ABCA1 elevating compounds | CV THERAPEUTICS, INC. | 2007-08-16 | — | — | US | disclosed |
| US-20070010544-A1 | ABCA1 elevating compounds | CV THERAPEUTICS, INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191379-A1 | ABCA1 elevating compounds | ABCD3, ABCB4, CETP | HTR6 2223/4885HTR2C 3634/4885HTR2B 3502/4885 |
| US-20080293757-A1 | ABCA1 ELEVATING COMPOUNDS | ABCD3, ABCB4, CETP | HTR6 2223/4885HTR2C 3634/4885HTR2B 3502/4885 |
| US-20070010544-A1 | ABCA1 elevating compounds | ABCD3, ABCB4, CETP | HTR6 2223/4885HTR2C 3634/4885HTR2B 3502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.